Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides | Zendy

Felicity de Cogan | Zendy; Lisa J. Hill | Zendy; A.C. Lynch | Zendy; Peter Morgan-Warren | Zendy; Judith Lechner | Zendy; Matthew R. Berwick | Zendy; Anna F. A. Peacock | Zendy; Mei Chen | Zendy; Robert A. H. Scott | Zendy; Heping Xu | Zendy; Ann Logan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides

Author(s) -

Felicity de Cogan,

Lisa J. Hill,

A.C. Lynch,

Peter Morgan-Warren,

Judith Lechner,

Matthew R. Berwick,

Anna F. A. Peacock,

Mei Chen,

Robert A. H. Scott,

Heping Xu,

Ann Logan

Publication year - 2017

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.16-20072

Subject(s) - bevacizumab , medicine , posterior segment of eyeball , ranibizumab , eye drop , in vivo , intravitreal administration , ophthalmology , pharmacology , choroidal neovascularization , ex vivo , retinal , surgery , chemotherapy , biology , microbiology and biotechnology

To evaluate the efficacy of anti-VEGF agents for treating choroidal neovascularization (CNV) when delivered topically using novel cell-penetrating peptides (CPPs) compared with delivery by intravitreal (ivit) injection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research